U.S. Based Cellular Therapy for CHF & AFib
The Only U.S.-Based Patented Cell Therapy for CHF and AFib

A Breakthrough Treatment For Congestive Heart Failure

Kaorta targets key drivers that can contribute to congestive heart failure including inflammatory conditions. Designed to support heart performance and symptom improvement for AFib patients.

The therapy follows rigorous protocols, is administered in a controlled setting, and complies with FDA guidelines outlined in 21 CFR 1271.10, which define oversight under section 361 of the PHS Act and 21 CFR Part 1271.

Our Story & Impact

For years we have used this approach in neuropathy care. As we treated people, we began to see it could also help patients facing congestive heart failure and AFib, sometimes with changes reported in days.

Many patients arrive short of breath and limited in everyday movement. We have seen cases where after one infusion, patients reported major changes over the following weeks, staying out of AFib, and walking stairs again.

The name Kaorta® comes from the aorta, the main artery that leaves the heart. Today our focus is simple, help patients regain daily life while encouraging them to continue routine monitoring and care through their cardiologist after treatment.

Streamlined, stress-free guidance.

What's The Consultation Like?

  1. Book a consultation to discuss your symptoms, diagnosis history, and goals. We will talk through AFib and CHF details and help you understand what to expect from the process. Get in touch with us at +1 (504) 294-8333.

Fellowship-trained Doctor

Dr. Alan Cole

Dr. Alan Cole

A Real Breakthrough.

"We developed new infusion therapies so they can be safely infused into the patient. Resulting in astonishing clinical improvements in our patients."

9+ Years Pioneering Cellular Infusion Innovation

Training & Background

A fellowship-trained doctor who has spent 9+ years pioneering cellular infusion innovation, leading the creation of the only U.S.-based patented cell-therapy platform for congestive heart failure and AFib.

The Science Behind Kaorta®

Kaorta® uses a cellular based protocol that is the same treatment approach our team has used for years in neuropathy care, now applied to congestive heart failure and AFib patients. With Kaorta® many patients report noticing changes quickly, often within 1 to 2 days, though results vary from person to person.

What Treatment Day Looks Like

After the tissue has been processed by the lab, we setup the patients IV infusion for 1 Hour & 45 minutes. In some cases, follow-up infusions may be needed.

Why Patients Choose
Kaorta®

Some patients report rapid changes in breathing and daily function, sometimes as soon as the next day or within 1 to 2 days

Professional & Friendly Team

Meet Our Team

Commited To Always Being

Patient First

Kaorta® is guided by a physician led clinical team with an established protocol and a patient first mindset. Patients can expect clear screening, straightforward communication, and a strong emphasis on safety.

You have questions, we have answers.

Frequently Asked Questions

  1. Kaorta® is focused on adults commonly dealing with AFib and congestive heart failure. Most patients we see are age 55 and older. That being said, we have had success with younger patients as well.

Considering Kaorta® for Yourself or a Family Member?

Set up a consult and review the treatment schedule, travel plans and next steps.

+1 (504) 294-8333